Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density

Mark D. Hornstein, Hornstein MD, M D Hornstein, A. Albert Yuzpe, A A Yuzpe, Yuzpe AA, Burry K, K Burry, Kenneth A. Burry, Veasy C. Buttram, Buttram VC Jr, V C Buttram, Heinrichs LR, LeRoy Heinrichs, L R Heinrichs, R M Soderstrom, Soderstrom Rm, Richard M. Soderstrom, E Steinberger, Steinberger E, Emil Steinberger, Jin‐Sying Lin, J S Lin, Lin JS
Fertility and sterility · 1997 · vol. 67(6) , pp. 1013–1018 · doi:10.1016/s0015-0282(97)81432-x · PMID:9176437 · W2028010046
article OA: closed CC0 ⤵ 18 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study evaluated the efficacy, safety, and impact on bone mineral density of nafarelin retreatment in patients experiencing recurrent endometriosis symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo assess the efficacy, safety, and effect on bone mineral density of a 3-month course of retreatment with intranasal nafarelin acetate for recurrent symptoms of endometriosis.DesignMulticenter, open-label, nonrandomized clinical trial.SettingEleven hospital-based and private practices.Patient(s)Thirty-six women with endometriosis symptoms recurring after 3 or 6 months of treatment with nafarelin.Intervention(s)Nasal nafarelin 200 micrograms twice daily for 3 months.Main outcome measure(s)Assessments for dysmenorrhea, dyspareunia, pelvic pain, tenderness, and induration. Measurement of bone mineral density of the lumbar spine.Result(s)Improvements from admission to the end of retreatment were significant for dysmenorrhea, pelvic pain, tenderness, induration, and dyspareunia. Three months after retreatment ended, mean symptom scores for dysmenorrhea and pelvic tenderness, although worse than at the end of retreatment, were still significantly better than scores at admission. Mean bone mineral density 3 months after retreatment was 0.56% lower than before retreatment and 1.94% lower than before initial treatment.Conclusion(s)Three-month nafarelin retreatment for recurrent endometriosis symptoms was effective and safe.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosis

MeSH descriptors

Bone Density Endometriosis Hormones Nafarelin Administration, Intranasal Adult Bone Density Dysmenorrhea Dysmenorrhea Endometriosis Female Hormones Hormones Hormones Humans Middle Aged Nafarelin Nafarelin Nafarelin Pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Cited by (18)

Source provenance

europepmc
last seen: 2026-08-09T06:10:49.860119+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:52.568893+00:00
License: CC0 · commercial use OK